Association between implantable cardioverter-defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy

被引:3
|
作者
Kronborg, Mads Brix [1 ]
Johansen, Jens Brock [2 ]
Haarbo, Jens [3 ]
Riahi, Sam [4 ]
Philbert, Berit Thornvig [5 ]
Jorgensen, Ole Dan [6 ]
Nielsen, Jens Cosedis [1 ]
机构
[1] Aarhus Univ Hosp, Dept Cardiol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark
[2] Odense Univ Hosp, Dept Cardiol, Aarhus, Denmark
[3] Copenhagen Univ Hosp, Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark
[4] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark
[5] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Heart Lung & Vasc Surg, Odense, Denmark
来源
EUROPACE | 2018年 / 20卷 / 09期
关键词
Cardiac resynchronization therapy; Lead position; Implantable cardioverter-defibrillator; Heart failure; Ventricular tachycardia; VENTRICULAR TACHYARRHYTHMIAS; MADIT-CRT; TRIAL; IMPACT; PLACEMENT; RISK;
D O I
10.1093/europace/eux296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the impact of different right and left ventricular lead positions (RV-LP and LV-LP) on the risk of therapy for ventricular tachycardia/ventricular fibrillation in patients with a cardiac resynchronization therapy device (CRT-D). Methods and results We performed a large nationwide cohort study on patients in Denmark receiving a CRT-D device from 2008 to 2012 from the Danish Pacemaker and implantable cardioverter defibrillator (ICD) registry. Lead positions were registered during the implantation and categorized as anterior/lateral/posterior and basal/mid-ventricular/apical for the LV-LP, and as apical/non-apical for the RV-LP. Appropriate and inappropriate therapies were registered during follow-up via remote monitoring or at device interrogations. Time to event was summarized with Kaplan-Meier plots, and competed risk regression analysis was used to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Following variables were included in the analysis: gender, age, heart failure aetiology, New York heart association class, left ventricular ejection fraction, QRS duration, indication (secondary or primary prophylactic), RV-LP, LV-LP, and antiarrhythmic therapy. We included 1643 patients [mean age 68 (+/- 10) years, 1343 (83%) men]. After a mean of 2.0 years, 322 (20%) patients received appropriate and 66 (4%) patients received inappropriate therapy. The aHR for appropriate therapy with a non-apical RV-LP was 0.70 95% CI (0.55-0.87, P = 0.002) as compared with an apical. We observed no significant association between appropriate therapy and LV-LP in left anterior oblique or right anterior oblique views or inappropriate therapy between any lead positions. Conclusion An apical RV-LP is associated with an increased risk of appropriate therapy for ventricular tachyarrhythmia in patients with a CRT-D device.
引用
收藏
页码:E133 / E139
页数:7
相关论文
共 50 条
  • [31] Upgrade of implantable cardioverter-defibrillator to Cardiac Resynchronization Therapy with Defibrillator (CRT-D). In which patients shall we expect?
    Pruszkowska-Skrzep, P.
    Morawski, S.
    Lenarczyk, R.
    Kowalski, O.
    Czaicka, I.
    Chodor, P.
    Pluta, S.
    Sokal, A.
    Sredniawa, B.
    Kalarus, Z.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1073 - 1073
  • [32] Incidence of and predictors for appropriate implantable cardioverter-defibrillator therapy in patients with a secondary preventive implantable cardioverter-defibrillator indication
    Schaer, Beat
    Kuehne, Michael
    Reichlin, Tobias
    Osswald, Stefan
    Sticherling, Christian
    EUROPACE, 2016, 18 (02): : 227 - 231
  • [33] The eligibility of patients with an inherited cardiac disease for therapy with a subcutaneous implantable cardioverter-defibrillator
    Proost, V. M.
    Van der Stuijt, W.
    Pepplinkhuizen, S.
    Knops, R. E.
    Wilde, A. A. M.
    EUROPEAN HEART JOURNAL, 2022, 43 : 493 - 493
  • [34] Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis
    Hamon, David
    Algalarrondo, Vincent
    Gandjbakhch, Estelle
    Extramiana, Fabrice
    Marijon, Eloi
    Elbaz, Nathalie
    Selhane, Dounia
    Dubois-Rande, Jean-Luc
    Teiger, Emmanuel
    Plante-Bordeneuve, Violaine
    Damy, Thibaud
    Lellouche, Nicolas
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 562 - 568
  • [35] Indications for Pacemakers, Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Devices
    Samii, Soraya M.
    MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (04) : 795 - +
  • [36] Saving lives and reducing inappropriate device therapy: The MADIT family of implantable cardioverter-defibrillator and cardiac resynchronization therapy trials
    Moss, Arthur J.
    CARDIOLOGY JOURNAL, 2013, 20 (03) : 217 - 219
  • [37] Underutilization of β-Blockers in Patients Undergoing Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Procedures
    Hauptman, Paul J.
    Swindle, Jason P.
    Masoudi, Frederick A.
    Burroughs, Thomas E.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2010, 3 (02): : 204 - 211
  • [38] Update of implantable cardioverter/defibrillator and cardiac resynchronization therapy in heart failure
    Rami, T
    Shih, HT
    CURRENT OPINION IN CARDIOLOGY, 2004, 19 (03) : 264 - 269
  • [39] The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
    Yao, Guiqing
    Freemantle, Nick
    Calvert, Melanie J.
    Bryan, Stirling
    Daubert, Jean-Claude
    Cleland, John G. F.
    EUROPEAN HEART JOURNAL, 2007, 28 (01) : 42 - 51
  • [40] The economic impact of longevity of implantable cardioverter-defibrillator for cardiac resynchronization therapy from a healthcare service perspective
    Landolina, M.
    Morani, G.
    Curnis, A.
    Vado, A.
    Ammendola, E.
    D'Onofrio, A.
    Stabile, G.
    Crosato, M.
    Petracci, B.
    Ceriotti, C.
    Bontempi, L.
    Morosato, M.
    Ballari, G. P.
    Gasparini, M.
    EUROPEAN HEART JOURNAL, 2016, 37 : 692 - 692